Pacific Biosciences
PACB
155 hedge funds and large institutions have $809M invested in Pacific Biosciences in 2018 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 45 increasing their positions, 25 reducing their positions, and 34 closing their positions.
109% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 34
89% more call options, than puts
Call options by funds: $8.75M | Put options by funds: $4.62M
80% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 25
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more capital invested
Capital invested by funds: $590M → $809M (+$220M)
31% more funds holding
Funds holding: 118 → 155 (+37)
1.4% less ownership
Funds ownership: 74.5% → 73.1% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$58.8M |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$41.7M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$28.2M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$27M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$70.1M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$65.9M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$49.3M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$43.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28M |
PACB Hedge Fund Activity: Q4 2018 in Review
155 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2018, worth a combined $809M — up 37% from $590M a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new PACB positions and 34 closed out — a net gain of 37 holders — while 45 added to existing stakes and 25 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $58.8M. The largest seller was Consonance Capital Management, cutting an estimated $70.1M.
- 155 institutional investors held Pacific Biosciences (PACB) as of Q4 2018, up from 118 in Q3 2018.
- Funds reported $809M of Pacific Biosciences stock for Q4 2018, up 37% quarter-over-quarter.
- 71 funds opened new Pacific Biosciences positions in Q4 2018 and 34 closed out, a net change of +37 holders.
- The largest Pacific Biosciences buyer in Q4 2018 was Magnetar Financial, an estimated $58.8M added.
- The largest Pacific Biosciences seller in Q4 2018 was Consonance Capital Management, an estimated $70.1M sold.
Based on aggregated 13F filings for Q4 2018.